Contact us Demo our platform

ON DEMAND WEBINAR

On Demand: Leveraging Metabolomics for Biomarker Discovery in a Multiomics Landscape

Metabolomics has emerged as a key technology in oncology research, offering a comprehensive view of the biochemical processes and the resulting impact on cancer progression and treatment. This field has evolved from merely cataloguing metabolites as part of cellular biochemistry to recognizing their significant roles as regulators of cancer-specific phenotypes, including malignant transformation, cell proliferation, and metastasis. The discovery of oncometabolites like 2-hydroxyglutarate in IDH1-mutated cancers underscores the importance of metabolites in directly influencing cancer pathways. Metabolomic profiling within the tumor microenvironment and circulation is now pivotal for understanding cancer mechanisms and identifying therapeutic targets.

This webinar will highlight the critical role of metabolomics in oncology, aiming to engage a diverse audience in discussions about the latest advancements in metabolomic technologies and their application in cancer research. A key focus will be on metabolomics’ ability to identify novel biomarkers in neuroblastoma, aiding in early detection, disease monitoring, and treatment evaluation in a challenging cancer phenotype.

Furthermore, we will explore the integration of metabolomics within the multiomics framework, emphasizing its indispensable role alongside genomics and transcriptomics. This integrative approach not only enriches our understanding of the molecular complexity of cancer but also supports the identification of molecular subtypes and informs personalized treatment strategies. As the final frontier in the multi-omics cascade, metabolomics reflects the ultimate phenotype and provides a direct link to the clinical picture, thereby enhancing precision medicine efforts in oncology.

You will learn:

  • Metabolites in Cancer Biology – Learn the history of oncometabolite identification, establishing cancer as a metabolic disease.

  • Biomarker Discovery in Neuroblastoma – Explore how metabolomics aids in early detection, disease monitoring, and treatment evaluation.

  • Multiomics Integration – Understand how metabolomics complements genomics and transcriptomics to further our functional understanding of cancer biology and refine cancer subtyping.

  • Precision Medicine & Clinical Impact – Discover how metabolomics links biochemical changes to clinical outcomes, enhancing precision oncology.

Program

Presenter
Title/Abstract
Louis Lichten, Ph.D.
Welcome and Introductions
Micaiah Ward, Ph.D.
Leveraging Metabolomics for Biomarker Discovery in a Multiomics Landscape
Louis Lichten, Ph.D.
Routine Solutions for Untargeted and Targeted Metabolomics
Micaiah Ward, Ph.D.
Integrated Bioinformatics Platform
Micaiah Ward, Ph.D.
Questions and Answers

Speakers

K
L

Miciah Ward, Ph.D.

Field Metabolomics Scientist, Metabolon

Dr. Micaiah Ward is a Field Metabolomics Scientist supporting Metabolon’s North America East Region and Population Health activities. Prior to joining Metabolon, Micaiah earned her Ph.D. in Cellular and Molecular Biology from Florida State University where her research incorporated genomics, transcriptomics and proteomics to investigate and characterize venoms from snakes, centipedes and scorpions. In addition, she used genome-wide association (GWAS) and evolve and resequencing (E&R) approaches to identify the genetic architecture of evolved venom resistance in fruit flies (Drosophila melanogaster). Micaiah then served as a Postdoctoral Research Fellow at Regeneron Pharmaceuticals, where she honed experience in immuno-oncology, infectious diseases, and CRISPR technology. Her broad scientific acumen and multi-omics expertise allows Micaiah to highlight the added value of metabolomics in moving the needle of scientific progress across basic and applied research areas in academia and industry.

K
L

Louis Lichten, Ph.D.

Business Development Executive at Metabolon

Louis is a Business Development Executive at Metabolon, specializing in metabolomics solutions for academic, government, and commercial research clients. With a PhD in Molecular Biology and a M.S. in Nutritional Sciences, Louis leverages his scientific knowledge to support researchers in integrating metabolomics into their studies. With 14 years of industry experience spanning genomics, transcriptomics, and proteomics, he brings a comprehensive multiomics perspective to guide clients in selecting the best analytical approaches for their research. Passionate about advancing scientific discovery, Louis is dedicated to fostering collaborations that drive meaningful insights in the life sciences.

WATCH WEBINAR NOW

Related Webinars

See All Webinars
✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.